CAR T-cell therapy in older patients: Efficacy and rates of immune-mediated toxicity
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients ≥65 years old with multiple myeloma.